Navigation Links
Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics
Date:6/3/2008

uisition is expected to close in the fourth quarter of 2008, subject to the following conditions:

-- Clearance by the relevant competition authorities.

-- No material adverse change at Innogenetics amounting to a loss greater

than EUR 10 million before the end of the acceptance period.

-- An acceptance threshold of at least 90% of the outstanding shares of

Innogenetics, or 75% if Innogenetics' articles of association are

modified to remove voting restrictions and introduce a "one share, one

vote" principle.

Financial Detail

Net of cash and other debt, the enterprise value of Gen-Probe's offer amounts to approximately EUR 219 million ($340 million) and is roughly 4.3 times Innogenetics' diagnostics revenue of approximately EUR 51 million in 2007. Gen-Probe expects to finance the transaction with cash currently on its balance sheet.

Gen-Probe expects to record charges for non-recurring cash and non-cash acquisition-related costs, primarily the write-off of in-process research and development, following the close of the tender offer. The size of these charges will not be determined, under the rules of purchase accounting, until an independent, third party valuation has been completed to allocate the excess of the purchase price over the assets and liabilities acquired.

On a GAAP basis, Gen-Probe expects the proposed acquisition to become accretive to its earnings per share (EPS) within 18 months of closing, and to be slightly dilutive to 2009 EPS.

On a non-GAAP basis, excluding acquisition-related charges and the expected increase in depreciation and amortization expense from acquired assets, Gen-Probe expects the proposed acquisition to be slightly dilutive to non-GAAP EPS in 2008, and neutral to slightly accretive to non-GAAP EPS in 2009.

These financial estimates assume that the proposed transaction closes in the fourth quarter of 2008.

UBS Investment Bank
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
2. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
3. Gen-Probe to Webcast Three Upcoming Presentations
4. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
5. Carl Hull Named President and Chief Operating Officer of Gen-Probe
6. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
7. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
8. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
9. Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
10. Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference
11. Lucy Shapiro, Ph.D., Elected to Gen-Probe Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
(Date:1/22/2015)... Calif. , Jan. 22. 2015  Varian Medical Systems (NYSE: ... software, has been honored for its commitment to sustainability with ... companies. Varian is the highest ranked healthcare equipment company among ... today during the World Economic Forum at Davos, ...
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... 2008, LEVERKUSEN, Germany, and PITTSBURGH, Pennysylvania, March 26, ... successfully completed its tender offer for the,outstanding shares of ... ).,The depositary for the offer has advised MEDRAD that, ... New York City time, on Tuesday, March 25, 2008,a ...
... Lung Cancer Patients Treated With CyberKnife System to ... (Nasdaq: ARAY ), a global leader in ... percent of CyberKnife centers,worldwide are now treating lung ... of lung cancer patients is growing,significantly as well, ...
... March 26 Vicus Therapeutics, LLC, an,oncology-focused, ... Vice President Clinical Research and Development, is,scheduled ... International,Molecular Medicine Tri-Conference on March 28st at ... Center in San Francisco. Dr. Rao will ...
Cached Biology Technology:Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period 2Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period 3CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide 2CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide 3CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide 4
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... advances in technology, it is important to upgrade biometric ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... of well-known and respected physicians, scientists, politicians, corporate ... for homeopathic medicine. Eleven U.S. Presidents, seven ... and C. Everett Koop are among those famous ... homeopathy. Perhaps most surprisingly is the evidence of ...
... which parasites interact with each other could help predict when ... group of scientists in the UK and the US has ... findings could lead to us being able to predict more ... occur. The team from Cardiff Universitys School of ...
... to multiply, are often regulated by switches that control ... Carolina State University scientists have discovered the way in ... turning one of its switches off, leading to uncontrolled ... In a paper published in the December 2007 ...
Cached Biology News:The surprising story of Charles Darwin and his homeopathic doctor 2The surprising story of Charles Darwin and his homeopathic doctor 3Can interacting pathogens explain disease patterns? 2Why the switch stays on 2Why the switch stays on 3